Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Special Category — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category

Other

Neoplasm by Special Category

CI-CAN-00000004Explore in graph →

Non-malignant21,349 active trials259 approved drugs3,859 evidence items

NCIt: C7062

Overview
Statistics
Survival
Genomics477
Variants & evidence3859
Drugs429
Trials95726
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,431)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,976–4,000 of 4,431 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
· Leuk Res · 2008 · PMID 18191450 · validated civic_curation pubmed
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
· Blood · 2006 · PMID 16772610 · validated civic_curation pubmed
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
· Clin Cancer Res · 2017 · PMID 27535980 · validated civic_curation pubmed
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
· Sci Transl Med · 2017 · PMID 28148839 · validated civic_curation pubmed
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
· Mol Cancer Ther · 2016 · PMID 27364904 · validated civic_curation pubmed
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
· Oncotarget · 2016 · PMID 27489350 · validated civic_curation pubmed
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
· J Clin Invest · 2013 · PMID 23585477 · validated civic_curation pubmed

Showing 3,976–4,000 of 4,431 publications

← Previous
1
…
159
160
161
…
178
Next →

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

· Blood · 2004 · PMID 15256420 · validated civic_curation pubmed

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

· Blood · 2004 · PMID 15304385 · validated civic_curation pubmed

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.

· Cancer Res · 2017 · PMID 28202511 · validated civic_curation pubmed

AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.

· Leukemia · 2007 · PMID 17330097 · validated civic_curation pubmed

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

· Cancer Res · 2015 · PMID 25952648 · validated civic_curation pubmed

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.

· Oncol Rep · 2012 · PMID 22246397 · validated civic_curation pubmed

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

· PLoS Med · 2006 · PMID 17177598 · validated civic_curation pubmed

Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.

· Mol Cancer · 2007 · PMID 17877814 · validated civic_curation pubmed

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

· Proc Natl Acad Sci U S A · 2008 · PMID 18287029 · validated civic_curation pubmed

A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.

· J Thorac Oncol · 2017 · PMID 28389374 · validated civic_curation pubmed

Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.

· Sci Rep · 2016 · PMID 27197561 · validated civic_curation pubmed

A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.

· Cell Death Dis · 2016 · PMID 27735949 · validated civic_curation pubmed

Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

· Int J Cancer · 2009 · PMID 19533750 · validated civic_curation pubmed

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

· Clin Cancer Res · 2018 · PMID 29127119 · validated civic_curation pubmed

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.

· Nat Commun · 2016 · PMID 27694828 · validated civic_curation pubmed

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.

· Oncogene · 2009 · PMID 18794803 · validated civic_curation pubmed

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.

· Clin Cancer Res · 2016 · PMID 26733615 · validated civic_curation pubmed

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

· Cancer Discov · 2017 · PMID 28274957 · validated civic_curation pubmed